In colorectal cancer cells, GLS confers a growth advantage, a pro-tumor microenvironment, and therapeutic resistance by regulating metabolic changes, and colorectal tumors with high expression of glutaminase (GLS) exhibit reduced T-cell infiltration and decreased cytotoxicity, leading to poor clinical prognosis (Yu et al., 2025). This evidence concerns the gene GLS and neoplasm.